-
2023
-
US FDA declines to approve AbbVie’s Parkinson’s disease therapy
-
FDA Approves Evkeeza for Kids With Ultra-Rare Cholesterol Disorder
-
EU Authorizes Dupixent for Young Kids With Severe Atopic Dermatitis
-
FDA Approves Rezzayo, a Novel Echinocandin
-
FDA Approves Sandoz’s Citrate-Free Adalimubab Formulation
-
AbbVie Hits Snag for Parkinson’s Disease Candidate
-
AstraZeneca and Ionis build case for amyloidosis drug eplontersen
-
FDA Approves First-Ever Treatment for Activated Phosphoinositide 3-Kinase Delta Syndrome
-
NICE Recommends Upstaza for Rare Genetic Disorder
-
Incyte Gets CRL for Jakafi Extended-Release Tablets